Extended drug cessation appears feasible in exceptional responders with HER2+ de novo metastatic breast cancer, with significantly better survival compared with non-exceptional responders.
Ozlem Soran
Advertisement
Articles by Ozlem Soran
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Risvutatug Rezetecan Improves Overall Survival in Relapsed SCLC Trial
2
Dostarlimab Yields Sustained Complete Responses in dMMR/MSI-H Rectal Cancer
3
FDA Accepts NDA for Mezigdomide Combo in R/R Multiple Myeloma
4
FDA Rejects Rivoceranib/Camrelizumab in First-Line Unresectable HCC
5